Suaybaguio Saul B, Jamias Jade D, Briones Marla Vina A
Department of Internal Medicine, Section of Gastroenterology, East Avenue Medical Center, Diliman, Quezon City, Philippines.
Liver Center, Internal Medicine Department, National Kidney and Transplant Institute, Diliman, Quezon City, Philippines.
Acta Med Philipp. 2025 Jul 15;59(9):83-89. doi: 10.47895/amp.vi0.9694. eCollection 2025.
Gastrointestinal (GI) manifestations among COVID-19 patients are common; however, their relation with patient outcomes remains unclear. The study, therefore, aims to determine the association of GI manifestation with in-hospital mortality among end-stage renal disease patients (ESRD).
This is a retrospective cohort design. All 501 ESRD patients with COVID-19 and admitted to the National Kidney and Transplant Institute from June 2020 to 2021 were included. GI manifestation was defined as the presence of any of the following signs and symptoms on admission: dysgeusia, anorexia, abdominal pain, nausea, vomiting, diarrhea, and jaundice. The outcome of interest was in-hospital mortality, defined as death due to any cause during hospital stay. Stata17 was used for data analysis.
The overall prevalence of GI manifestation was 58.08% (95% CI: 53.63-62.45). The most common symptoms were abdominal pain (27.15%), loss of appetite (24.35%), and nausea (19.76%). Patients with GI manifestation had a higher proportion of stroke, lower median systolic blood pressure, and a lower proportion of abnormal oxygen saturation and diastolic blood pressure than those without GI manifestation. Across all clinical outcomes, only hospital stay significantly differ between those with and without GI manifestation. In-hospital mortality was 31.14% (95% CI: 27.10-35.39%) and showed no significant association with GI manifestation (OR= 0.94, p=0.749).
GI manifestation was common among ESRD patients with moderate-to-severe COVID-19. The inhospital mortality rate is also high; however, GI manifestation was not associated with this outcome. Meanwhile, GI manifestation leads to longer hospital stay.
新冠病毒病（COVID-19）患者的胃肠道（GI）表现很常见；然而，它们与患者预后的关系仍不明确。因此，本研究旨在确定胃肠道表现与终末期肾病（ESRD）患者院内死亡率之间的关联。
这是一项回顾性队列研究设计。纳入了2020年6月至2021年期间收治于国家肾脏与移植研究所的所有501例患有COVID-19的ESRD患者。胃肠道表现定义为入院时出现以下任何体征和症状：味觉障碍、食欲不振、腹痛、恶心、呕吐、腹泻和黄疸。感兴趣的结局是院内死亡率，定义为住院期间因任何原因导致的死亡。使用Stata17进行数据分析。
胃肠道表现的总体患病率为58.08%（95%置信区间：53.63 - 62.45）。最常见的症状是腹痛（27.15%）、食欲不振（24.35%）和恶心（19.76%）。有胃肠道表现的患者中风比例更高，收缩压中位数更低，异常血氧饱和度和舒张压比例低于无胃肠道表现的患者。在所有临床结局中，只有住院时间在有和无胃肠道表现的患者之间存在显著差异。院内死亡率为31.14%（95%置信区间：27.10 - 35.39%），与胃肠道表现无显著关联（比值比 = 0.94，p = 0.749）。
胃肠道表现在中重度COVID-19的ESRD患者中很常见。院内死亡率也很高；然而，胃肠道表现与该结局无关。同时，胃肠道表现会导致住院时间延长。
